First-In-Man Experience of Adipose-Derived Stem Cell Transplantation in the Treatment of Patients with an Acute ST-Elevation Myocardial Infarction (APOLLO Trial - Cytori).
H.J. Duckers*; Patrick Serruys**
* Erasmus Medical Centre, Erasmus University, Rotterdam, the Netherlands
** Department of Interventional Cardiology, Erasmus Medical Centre, Erasmus University, Rotterdam, the Netherlands
A number of pilot trials as well as two larger randomized trials have shown a significant benefit of treatment with bone marrow mononuclear cells in acute myocardial infarction (AMI). Autologous adipose-derived regenerative cells (ADRCs) can be obtained from subcutaneous adipose tissue in sufficient amount for therapy and require no cell culture step before use. While similar to bone marrow derived adult stem cells in differentiation potential, the usual abundance of adipose tissue in human patients and the higher frequency of adult stem cells per unit mass (including mesenchymal stem cells and EPCs) allows fast isolation of an efficacious number of cells without having to culture expand them. Preparation of therapeutic doses of ADRCs involves no cell culture and can be achieved in less than two hours from the time of donor tissue acquisition. This allows for treatment during the same procedure as the harvest of the adipose tissue and can thus be appended to the primary percutaneous coronary interventional treatment (PCI) of an acute myocardial infarction.